Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21402090 | 0.93 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL21402085 | 0.92 | MAPK11 (0.36) | IDO1TDO2BTKCYP3A4 | |
| SCHEMBL21402087 | 0.92 | MAPK11 (0.36) | IDO1TDO2BTKCYP3A4 | |
| SCHEMBL21407497 | 0.92 | MAPK11 (0.36) | IDO1TDO2BTKCYP3A4 | |
| SCHEMBL20002451 | 0.91 | IDO1 (0.36) | IDO1TDO2BTK | |
| SCHEMBL21407499 | 0.90 | CNR1 (0.35) | IDO1TDO2CYP3A4 | |
| SCHEMBL21402068 | 0.90 | CNR1 (0.42) | IDO1TDO2BTKCYP3A4 | |
| SCHEMBL21402088 | 0.90 | JAK3 (0.39) | IDO1TDO2 | |
| SCHEMBL21402065 | 0.90 | MAPK11 (0.41) | EPHX2IDO1TDO2CYP3A4 | |
| SCHEMBL20002089 | 0.90 | EPHX2 (0.37) | EPHX2IDO1TDO2PIK3CDBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | EPHX2 1553/4885IDO1 1/4885TDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.